EN DE

Eiko Lifesciences Ltd (EIKO) Fair Value & Analysis

Basic Materials · IN · Market cap ₹719M

EL Eiko Lifesciences Ltd EIKO · BSE
Price₹47.55
Fair Value₹53.28
Upside+12.1%
Quality49/100
Watch Eiko Lifesciences Ltd for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 8.5% net margin
Low debt · generates free cash flow
Ranks above peers (11/13)
Narrow moat 42/100
Evidence: High Range ₹34.98 – ₹66.60 Share as image

Fair value as of: Aug 13, 2026

From 23 valuation models · updated 6 days ago

Below-average quality, screening 12% undervalued on our models.

What matters now

  • A fairly wide model range (₹34.98 to ₹66.60) leaves room in how you read the outcome.
  • Our model range runs from ₹34.98 (bear) to ₹66.60 (bull), base ₹53.28. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 49/100 (below-average quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

₹86.66 ₹19.63 Fair Value ₹53.28 Sep 2020 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹19.63 – ₹86.66 · fair‑value band ₹34.98 – ₹66.60 · the ₹47.55 price screens below the ₹53.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Eiko Lifesciences Ltd (EIKO) currently trades at ₹47.55, while our model-based Fair Value estimate is ₹53.28, implying the stock looks roughly 12.1% undervalued today. The Quality Score stands at 49/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Eiko Lifesciences Ltd generated revenue of ₹527M at a net margin of 8.5%. Revenue grew 62.7% year over year. It earns a return on equity of 8.4%. Net debt stands at ₹44.1M. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹34.98 (bear case) to ₹66.60 (bull case); at ₹47.55, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -68% fair-value upside, at 12%, EIKO screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF ₹27.66 ₹42.44 ₹65.68 80
Rev-Margin DCF ₹46.82 ₹82.55 ₹156.92 74
ROIC Compounder ₹35.65 ₹39.51 ₹42.72 72
All 23 models by family
DCF Models
FCF DCF ₹29.03 ₹38.99 ₹68.76 38
5Y Revenue Exit ₹42.86 ₹73.17 ₹136.98 39
5Y EBITDA Exit ₹41.17 ₹69.76 ₹125.91 41
5Y P/E Exit ₹41.91 ₹87.65 ₹150.48 38
10Y Revenue Exit ₹36.90 ₹80.90 ₹111.65 36
10Y EBITDA Exit ₹37.23 ₹77.58 ₹149.15 37
10Y P/E Exit ₹37.73 ₹79.05 ₹147.93 35
Earnings-Based
Graham-Dodd ₹21.31 ₹148.63 ₹208.58 54
Lynch FV ₹76.79 ₹109.70 ₹142.61 50
PEG = 1.0 ₹76.79 ₹109.70 ₹142.61 46
EPV ₹35.65 ₹39.51 ₹42.72 59
Multiples
P/E Multiple ₹39.96 ₹53.28 ₹66.60 63
P/S Multiple ₹39.96 ₹53.28 ₹66.60 58
P/B Multiple ₹39.96 ₹53.28 ₹66.60 55
EV/EBIT ₹54.36 ₹70.03 ₹85.69 53
EV/EBITDA ₹46.24 ₹59.20 ₹72.17 54
EV/Revenue ₹45.94 ₹62.47 ₹79.00 43
Asset-Based
NCAV (Graham) ₹23.97 ₹32.12 ₹47.94 50
Growth DCF
Growth DCF ₹27.66 ₹42.44 ₹65.68 80
Rev-Margin DCF ₹46.82 ₹82.55 ₹156.92 74
Economic Profit
Residual Income ₹36.05 ₹36.68 ₹35.54 61
ROIC Compounder ₹35.65 ₹39.51 ₹42.72 72
Growth Earnings
Growth-Adj P/E ₹94.47 ₹134.96 ₹175.45 68

Widest divergence: Growth Earnings (₹134.96) versus Asset-Based (₹32.12). Highest evidence: Growth DCF (80).

Notify me when EIKO reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) ₹527M
Revenue growth (YoY) +62.7%
Net margin 8.5%
Return on equity 8.4%
Free cash flow ₹22.8M FY2026
P/E ratio 14.8
More key figures
Operating margin 11.1%
EPS (TTM) ₹3.19
EPS growth (YoY) +27.9%
Net debt ₹44.1M FY2022

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 49/100

Of which business quality 51 · Market factors (momentum, volatility) 37

Profitability 36
Margins and returns on capital today
Quality Growth 82
Are margins and returns improving?
Cashflow 40
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 74
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 18
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Eiko LifeSciences Limited manufactures and sells specialty and fine chemicals in India. The company operates through Specialty Chemicals; Pharma Intermidiates; Food Additives; Oleo Chemicals; and Cosmetic Ingredients segments. The company offers organic and inorganic specialty chemicals.

Full company description

Eiko LifeSciences Limited manufactures and sells specialty and fine chemicals in India. The company operates through Specialty Chemicals; Pharma Intermidiates; Food Additives; Oleo Chemicals; and Cosmetic Ingredients segments. The company offers organic and inorganic specialty chemicals. Its products are used in pharmaceuticals, agrochemicals, aroma chemicals, electronic chemicals, etc. In addition, the company is involved in processing, formulating, producing, buying, selling, and exporting of specialty and fine chemicals. The company was formerly known as Narendra Investments (Delhi) Limited and changed its name to Eiko LifeSciences Limited in June 2021. Eiko LifeSciences Limited was incorporated in 1977 and is based in Thane, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Eiko Lifesciences Ltd reported revenue of ₹527M in FY2026 versus ₹254M in FY2022, a compound +20.0%/yr. Reported net income was ₹45.0M in FY2026, compounding +58.9%/yr from FY2022.

Growth Quality 76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2026)
₹527M
Latest YoY
+39.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+42.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+33.7%
Revenue +20.0%/yr
FY22 ₹254M
FY23 ₹183M
FY24 ₹279M
FY25 ₹377M
FY26 ₹527M
Net income +58.9%/yr
FY22 ₹7.1M
FY23 ₹7.7M
FY24 ₹7.5M
FY25 ₹21.1M
FY26 ₹45.0M

Watch EIKO: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Eiko Lifesciences Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EIKO

Peer Group

Specialty Chemicals · 675 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 49 · Below median
Fair Value upside +12% · Above median
Return on equity (TTM) 8% · Above median
Return on assets 5% · Above median
Net margin (TTM) 9% · Above median
Operating margin (TTM) 11% · Above median
Revenue growth 63% · Top 25%
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

P/E (TTM) 14.8× · Cheaper than 75% of peers
P/B 1.05× · Cheaper than median
P/S (TTM) 1.37× · Pricier than median
P/FCF 0.3× · Cheaper than median
EV/EBITDA 8.3× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE49 · sector 0
FUTURE100 · sector 19
PAST34 · sector 23
HEALTH98 · sector 95
DIVIDEND0 · sector 30

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $479.43 $222.03 -54%
Wanhua Chemical Group 600309 ¥75.06 ¥68.03 -9%
Asian Paints Limited ASIANPAINT ₹2,630 ₹696.23 -74%
Solar Industries India Limited SOLARINDS ₹18,730 ₹2,793 -85%
Pidilite Industries Limited PIDILITIND ₹1,702 ₹351.84 -79%
PT Chandra Asri Pacific Tbk TPIA 2,160 IDR 2,322 IDR +8%
Berger Paints India Limited BERGEPAINT ₹541.00 ₹156.35 -71%
Gujarat Fluorochemicals Limited FLUOROCHEM ₹4,680 ₹724.88 -85%
Himadri Speciality Chemical Limited HSCL ₹778.15 ₹248.63 -68%
Enaex S.A ENAEX 25,050 CLP 23,574 CLP -6%

Compare Eiko Lifesciences Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Eiko Lifesciences Ltd (EIKO) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of ₹53.28 versus a price of ₹47.55, about +12% (undervalued).
What is the fair value of EIKO?
Our model-based fair value for Eiko Lifesciences Ltd is ₹53.28 (as of Aug 13, 2026), built from audited fundamentals. The current price: ₹47.55.
What is the quality score of EIKO?
Eiko Lifesciences Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Eiko Lifesciences Ltd (EIKO)?
Eiko Lifesciences Ltd reported trailing-twelve-month revenue of about ₹527M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of EIKO?
The net profit margin of Eiko Lifesciences Ltd is about 8.5%, meaning it keeps roughly 8.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Eiko Lifesciences Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.